Dr. Friedrich von Bohlen und Halbach is managing partner at Dievini Hopp Biotech Holding GmbH & Co.KG, the company managing the life science activities and investments of Dietmar Hopp. In addition, he is board member/Beirat of: Apogenix GmbH, Curacyte AG, CureVac GmbH, Cosmo Pharmaceuticals SpA, Cytonet GmbH, Heidelberg Pharma AG, Life Biosystems AG, Sygnis Pharma AG and Wilex AG.
Dr. von Bohlen und Halbach has more than 10 years of entrepreneurial experience in the Life Sciences. He holds a diploma in biochemistry from the University of Zurich and a PhD in neurobiology from the Swiss Federal Institute of Technology (ETH) in Zurich.